
TY  - JOUR
TI  - Abstracts
JO  - Pharmacoepidemiology and Drug Safety
JA  - Pharmacoepidemiol Drug Saf
VL  - 24
IS  - S1
SN  - 1053-8569
UR  - https://doi.org/10.1002/pds.3838
DO  - doi:10.1002/pds.3838
SP  - 1
EP  - 587
PY  - 2015
ER  - 

TY  - JOUR
TI  - 43. Jahrestagung Physiologie u. Pathologie der  Fortpflanzung,  gleichzeitig  35. Veterinär-Humanmedizinische Gemeinschaftstagung  München, 24. – 26. Februar 2010
JO  - Reproduction in Domestic Animals
VL  - 45
IS  - s1
SN  - 0936-6768
UR  - https://doi.org/10.1111/j.1439-0531.2009.01589.x
DO  - doi:10.1111/j.1439-0531.2009.01589.x
SP  - 1
EP  - 61
PY  - 2010
ER  - 

TY  - JOUR
TI  - Abstract
JO  - Journal of Thrombosis and Haemostasis
JA  - Journal of Thrombosis and Haemostasis
VL  - 5
IS  - S2
SN  - 1538-7933
UR  - https://doi.org/10.1111/j.1538-7836.2007.tb00029.x
DO  - doi:10.1111/j.1538-7836.2007.tb00029.x
SP  - P-T-401
EP  - P-T-700
PY  - 2007
ER  - 

TY  - JOUR
TI  - Oral Session
JO  - Respirology
VL  - 15
IS  - s2
SN  - 1323-7799
UR  - https://doi.org/10.1111/j.1440-1843.2010.01864.x
DO  - doi:10.1111/j.1440-1843.2010.01864.x
SP  - 26
EP  - 54
PY  - 2010
ER  - 

TY  - JOUR
TI  - Tuesday, December 4, 2007 Subcortical Control of Cortical Excitability 11:00 a.m.-12:30 p.m.
JO  - Epilepsia
VL  - 48
IS  - s6
SN  - 0013-9580
UR  - https://doi.org/10.1111/j.1528-1167.2007.01252_14.x
DO  - doi:10.1111/j.1528-1167.2007.01252_14.x
SP  - 410
EP  - 410
PY  - 2007
AB  - Robert S. Fisher 1 , Lucy Brown 2 and Karen Gale 3 ( 1 Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA ; 2 Albert Einstein College of Medicine, Yeshiva University, Bronx, NY and 3 Neurology and Neuroscience, Georgetown University School of Medicine, Washington, D.C., WA ) Summary: This symposium will evaluate the role of certain subcortical circuits in seizures and cortical excitability. Data show that thalamocortical, basal ganglia, midbrain and hindbrain circuits play important roles in seizure generation, conduction and modulation. The session will provide a basic overview of these systems and circuits, both functionally and anatomically. The thalamus uses systems able to synchronize or desynchronize electrical activity in wide regions of cortex. These thalamocortical systems play a role in generation of absence seizures and propagation of secondarily generalized seizures. The basal ganglia have a close relationship with the cortex, and may ?gate? activity through a widespread corticostriate system, thus potentially both enhancing and suppressing seizure activity. Midbrain and hindbrain circuits have been shown to have profound effects on seizures. The session will discuss how an understanding of subcortical-cortical networks can lead to therapeutic advances, with use of electrical brain stimulation or targeted pharmacotherapy as examples.
ER  - 

TY  - JOUR
TI  - Tuesday, December 4, 2007 Temporal Lobe Epilepsy: Discrete Focus or Spectrum Disorder? 9:00 a.m.-10:30 a.m.
JO  - Epilepsia
VL  - 48
IS  - s6
SN  - 0013-9580
UR  - https://doi.org/10.1111/j.1528-1167.2007.01252_13.x
DO  - doi:10.1111/j.1528-1167.2007.01252_13.x
SP  - 410
EP  - 410
PY  - 2007
AB  - Edward H. Bertram 1 , Gary Mathern 2 , Helen Cross 3 and Maria Thom 4 ( 1 Department of Neurology, University of Virginia, Charlottesville, VA ; 2 Department of Neurosurgery, UCLA, Los Angeles, CA ; 3 Institute of Child Health, University College London, London, United Kingdom and 4 Institute of Neurology, University College London, London, United Kingdom ) Summary: Mesial temporal lobe epilepsy (MTLE) has been synonymous with hippocampal sclerosis, such that the consensus is that the removal of the latter cures the former. There is increasing information, including recent epidemiological data regarding the long term outcomes of surgery, that suggests that the underlying basis for the disorder is more extensive than originally thought. The ultimate question for improving outcomes is ?What is the true focus for MTLE?? Although our understanding of what constitutes the focus remains limited, there is evidence from surgical outcome, pathology, imaging and animal studies that the hippocampus alone is not the answer. Outcome studies show that only a small percentage of patients who are seizure free following surgery for MTLE can successfully stop medications and remain seizure free. Further there is evidence that the number of patients in remission falls steadily, even after a period of seizure freedom. These observations suggest that the seizure focus has not been completely removed. Studies of the temporal lobe pathology demonstrate changes that are variable but which extend beyond the hippocampus. Imaging has been a key factor in identifying structural abnormalities, but we may be missing key pieces of information that could identify the focus more precisely. Animal studies indicate that the ictal onset zone may be extensive and extend well beyond the hippocampus, but a true understanding of the physical substrate for seizure initiation still eludes us. This session is asking questions for which we only have partial answers. What do we know now about the seizure focus in MTLE? What do we need to know to have better outcomes? We don't have any good answers for either question other than a) not enough and b) a lot more. We hope this session will stimulate the participants to fill in the many gaps that now exist.
ER  - 

TY  - JOUR
TI  - Paper Abstract
JO  - Journal of the American Geriatrics Society
JA  - J Am Geriatr Soc
VL  - 66
IS  - S2
SN  - 0002-8614
UR  - https://doi.org/10.1111/jgs.15376
DO  - doi:10.1111/jgs.15376
SP  - S1
EP  - S369
PY  - 2018
ER  - 

TY  - JOUR
TI  - PODIUM SESSIONS
JO  - The Journal of Sexual Medicine
VL  - 8
IS  - s5
SN  - 1743-6095
UR  - https://doi.org/10.1111/j.1743-6109.2010.02546_1.x
DO  - doi:10.1111/j.1743-6109.2010.02546_1.x
SP  - 369
EP  - 383
PY  - 2011
ER  - 

TY  - JOUR
TI  - Abstracts of the ESRS, Prague 2004
JO  - Journal of Sleep Research
VL  - 13
IS  - s1
SN  - 0962-1105
UR  - https://doi.org/10.1111/j.1365-2869.2004.00410.x
DO  - doi:10.1111/j.1365-2869.2004.00410.x
SP  - 1
EP  - 832
PY  - 2004
ER  - 

TY  - JOUR
TI  - ABSTRACTS FOR INVITED PRESENTATIONS
JO  - Artificial Organs
VL  - 21
IS  - 6
SN  - 0160-564X
UR  - https://doi.org/10.1111/j.1525-1594.1997.tb00507.x
DO  - doi:10.1111/j.1525-1594.1997.tb00507.x
SP  - 473
EP  - 577
PY  - 1997
ER  - 

TY  - JOUR
TI  - Abstracts-Posters
JO  - Alcoholism: Clinical and Experimental Research
JA  - Alcohol Clin Exp Res
VL  - 38
IS  - s1
SN  - 0145-6008
UR  - https://doi.org/10.1111/acer.12451
DO  - doi:10.1111/acer.12451
SP  - 1A
EP  - 292A
PY  - 2014
ER  - 

TY  - JOUR
TI  - 10th Annual meeting of French Society of Pharmacology, 73rd Annual meeting of Society of Physiology, 27th pharmacovigilance meeting, 54th APNET Seminar and 4th CHU CIC meeting (Corum Montpellier 10-12 April 2006)
JO  - Fundamental & Clinical Pharmacology
VL  - 20
IS  - 2
SN  - 0767-3981
UR  - https://doi.org/10.1111/j.1472-8206.2006.00409.x
DO  - doi:10.1111/j.1472-8206.2006.00409.x
SP  - 145
EP  - 234
PY  - 2006
ER  - 

TY  - JOUR
TI  - Abstracts of the papers presented at the 43rd Annual Meeting of The American Society of Dermatopathology
JO  - Journal of Cutaneous Pathology
VL  - 34
IS  - 1
SN  - 0303-6987
UR  - https://doi.org/10.1111/j.1600-0560.2006.00691.x
DO  - doi:10.1111/j.1600-0560.2006.00691.x
SP  - 79
EP  - 138
PY  - 2007
ER  - 

TY  - JOUR
TI  - Acute coronary syndromes, myocardial infarction, thrombectomy and vulnerable plaque
JO  - Catheterization and Cardiovascular Interventions
JA  - Cathet. Cardiovasc. Intervent.
VL  - 87
IS  - S2
SN  - 1522-1946
UR  - https://doi.org/10.1002/ccd.26513
DO  - doi:10.1002/ccd.26513
SP  - S1
EP  - S169
PY  - 2016
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Basic & Clinical Pharmacology & Toxicology
JA  - Basic Clin Pharmacol Toxicol
VL  - 126
IS  - S1
SN  - 1742-7835
UR  - https://doi.org/10.1111/bcpt.13376
DO  - doi:10.1111/bcpt.13376
SP  - 10
EP  - 137
PY  - 2020
ER  - 

TY  - JOUR
TI  - SIOP Abstracts
JO  - Medical and Pediatric Oncology
JA  - Med. Pediatr. Oncol.
VL  - 39
IS  - 4
SN  - 0098-1532
UR  - https://doi.org/10.1002/mpo.10223
DO  - doi:10.1002/mpo.10223
SP  - 220
EP  - 423
PY  - 2002
ER  - 

TY  - JOUR
AU  - Freemont, A. J.
AU  - Watkins, A.
AU  - Le Maitre, C.
AU  - Jeziorska, M.
AU  - Hoyland, J. A.
TI  - Current understanding of cellular and molecular events in intervertebral disc degeneration: implications for therapy
JO  - The Journal of Pathology
JA  - J. Pathol.
VL  - 196
IS  - 4
SN  - 0022-3417
UR  - https://doi.org/10.1002/path.1050
DO  - doi:10.1002/path.1050
SP  - 374
EP  - 379
KW  - intervertebral disc degeneration
KW  - angiogenic molecules
KW  - neurogenic molecules
KW  - cytokines
PY  - 2002
AB  - Abstract Until recently, material removed from the intervertebral disc (IVD) at surgery consisted either of ?loose bodies? from the centre of the IVD or discal tissue displaced (prolapsed) into the intervertebral root or spinal canals. This material is best regarded as a by-product of disc degeneration and therefore not representative of the disease process itself. Recent advances in surgical techniques, particularly anterior fusion, in which large segments of the anterior part of the IVD are excised with the anatomical relationships between different components intact, have generated material that can be investigated with modern molecular and cell biological techniques. This is an important area of study because degeneration of the lumbar IVDs is associated, perhaps causally, with low back pain, one of the most common and debilitating conditions in the West. ?Degeneration? carries implications of inevitable progression of wear-and-tear associated conditions. Modern research on human IVD tissue has shown that this is far from the case and that disruption of the micro-anatomy described as degeneration is an active process, regulated by locally produced molecules. The exciting consequence of this observation is the possibility of being able to inhibit or even reverse the processes of degeneration using targeted therapy. Copyright ? 2002 John Wiley & Sons, Ltd.
ER  - 

AU  - Huang, Annie
AU  - Bartels, Ute
AU  - Bouffet, Eric
C7  - pp. 52-61
TI  - Pediatric Spinal Cord Tumors
SN  - 9781405153508
UR  - https://doi.org/10.1002/9781444315134.ch5
DO  - doi:10.1002/9781444315134.ch5
SP  - 52-61
KW  - Pediatric Spinal Cord Tumors
KW  - central nervous system (CNS)
KW  - magnetic resonance imaging (MRI)
KW  - Neurofibromatosis (NF)
KW  - primitive neuroectodermal tumors PNET)
KW  - progression free survival (PFS)
KW  - Society for Paediatric Oncology (SIOP)
KW  - primitive neuroectodermal tumors Disease specific issues
KW  - Strategies for follow up and important late effects
PY  - 2002
AB  - Summary This chapter contains sections titled: General overview Disease specific issues Strategies for follow up and important late effects Conclusions References
ER  - 

TY  - JOUR
TI  - Abstracts from the American Academy of Pediatrics Section on Cardiology and Cardiac Surgery (SOCCS)
JO  - Congenital Heart Disease
JA  - Congenital Heart Disease
VL  - 11
IS  - 5
SN  - 9781405153508
UR  - https://doi.org/10.1111/chd.12421
DO  - doi:10.1111/chd.12421
SP  - 468
EP  - 530
PY  - 2016
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Artificial Organs
VL  - 29
IS  - 9
SN  - 9781405153508
UR  - https://doi.org/10.1111/j.1525-1594.2005.01114_1.x
DO  - doi:10.1111/j.1525-1594.2005.01114_1.x
SP  - 716
EP  - 787
PY  - 2005
ER  - 
